Enhancing Prevention with Postivies Evaluation Center

Enhancing Prevention with Postivies Evaluation Center

Culturally Appropriate Interventions of Outreach, Access and Retention among Latina/o Populations Initiative Evaluation and Technical Assistance Center (ETAC) University of California, San Francisco Outline

Goal of initiative Goal of cross-site evaluation Cross-site evaluation framework Cross-site evaluation methods Eligibility Global unique ID Process evaluation Outcomes evaluation Economic evaluation Timeline Goal of Initiative To enhance HIV testing and diagnosis

among out-of-care Latino/as, and to link and retain these populations in high quality HIV care To engage intervention approaches tailored to Latino cultural beliefs as they relate to health seeking behavior Goal of Cross-site Evaluation To facilitate and conduct a rigorous evaluation of innovative and effective service delivery interventions for Latino/as living with HIV across demonstration sites. Evaluation Components

Quantitative HIV testing data Interventio n exposure Medical data abstraction Participant survey

Costing Qualitative Key informant interviews Participant interviews Local evaluation Cross-Site Quantitative

Evaluation Objectives To assess the effect of demonstration projects on: Engagement in HIV care continuum, and Patient health outcomes. To assess how pre-disposing factors, enabling factors and need mediate or moderate the effectiveness of demonstration projects Identification of factors guided by Transnational Framework specific to Latino/a experiences in the US

Objectives To assess the cost, cost-efficiency and costeffectiveness of demonstration projects Evaluation Theory Behavioral Model (Andersen, 1968, 1995) Predisposin g Factors Enabling Factors Need

Health Behavior Traditional Populations Predisposing Factors Demographics - Age - Gender - Relationship status Health Beliefs - Knowledge of healthcare resources - Satisfaction with HIV care

- Patient/provider communication Social Structure - Education - Employment - Faith traditions Enabling Factors Need Personal/Family Evaluated Health Resources

- HIV-related health status - Income - Health Insurance - Social support Community Resources - HIV healthcare resources Evaluation Theory Behavioral Model for Vulnerable Populations (Gelberg, Andersen, Leake 2000) Predisposin g Factors

Traditiona l population s Vulnerable population s Enabling Factors Traditiona l population

s Vulnerable population s Need Health Behavior Vulnerable Populations Predisposing Factors Enabling Factors

Need Social Structure - Transgender - Ethnicity - Skin color - Sexual orientation Lived Experience - Housing - Incarceration - HIV disclosure - Depression - Drug use

-Intimate partner violence Cultural Beliefs - Racial socialization Stigma - HIV, MSM, transgender, criminal record Personal/Family Resources - Competing needs - Public benefits - Coping skills - Transportation Community Resources

- Social service resources No additional factors Evaluation Theory Behavioral Model for Transnational Populations (proposed) Transnational Populations Predisposing Factors Enabling Factors Need

Health Beliefs - Knowledge of healthcare resources for immigrants Lived Experience - Country of origin - Migration - Transnational travel - Acculturation - English language literacy Cultural beliefs - Familismo, Machismo, Marianismo, Fatalismo Stigma

- National origin Personal/Family No additional factors Resources - Transnational social support - Economic transnationalism - Transnational communication - Transnational information sources Community Resources -Transnational density

- Transnational HIV medical provider Evaluation Framework Innovative Interventions Stigma reduction Community engagement Identification Outreach Social network testing Linkage

Patient navigation Retention Case management Cross-site Evaluation Primary Outcomes HIV Care Continuum HIV positivity Late HIV diagnosis Linkage to HIV medical care Retention in HIV medical care

Antiretroviral therapy Viral suppression Cross-site Evaluation Cross-site Quantitative Evaluation Methods HIV Testing Aggregate data Number tested Number tested HIV-positive Number enrolled

Number of new HIV diagnoses Number enrolled Eligibility Cross-site evaluation HIV-infected Mexican and Puerto Rican individuals HIV-infected Latino/Hispanic race

Identifies as Mexican or Puerto Rican Not fully engaged in HIV care Demonstration project participation Sites may include HIV-infected Latino/a individuals from other places of origin in demonstration interventions. However, these individuals will not be counted toward totals or included in the cross-site evaluation. Global Unique ID (GUI) GUI will be used to identify participants across all data collection methods GUI components

Name (first three letters of first and last name) Date of birth (month and year) Sex (on birth certificate) Gender (current) Race Ethnicity Zip code of current residence / sleeping (first three letters)

Participant Survey Eligible participants will be surveyed at baseline and every six months until six months before the end of the demonstration project. ETAC will be responsible for tool creation, training, technical support, maintenance of the web portal and data analysis. Participant Survey Demonstration sites will be responsible for consent, data collection and weekly transfer of data to secure web portal.

Ideally, data collection staff will not be intervention staff. If sites plan to conduct interviewer-administered surveys, these may NOT be conducted by intervention staff. Intervention Exposure Routinely collected data on units of service Community engagement Outreach HIV testing Patient navigation Case management

Intervention Exposure Demonstration sites will be responsible for uploading data for eligible participants every month to secure web portal. Demonstration sites will create and use their own tools for data collection Data must be submitted in a standardized format Intervention Exposure Data elements Date Participant ID Intervention provider Outreach worker, patient navigator, case manager, etc.

Provider type Peer, non-clinical provider, clinical provider Intervention target Stigma reduction, identification, linkage, retention, etc. Minutes Data Abstraction Abstraction of routinely collected data from: HIV testing Patient care HRSA Ryan White Services Report (RSR)

ETAC will be responsible for tool creation, training, technical support, maintenance of the web portal and data analysis. Demonstration sites will be responsible for uploading data for eligible participants every six months to secure web portal. Costing ETAC will work with demonstration sites to report the annual cost of planning and implementation of demonstration site interventions. Costing categories include:

Personnel Recurring costs Capital investment (one-time costs) Infrastructure (space) Costing Demonstration sites will be asked to report on costs by: Period (pre-implementation vs. post-implementation) Activity (community engagement, testing, patient navigation, case management) Intervention target (identification, linkage, retention, etc.) Source of resources (HRSA SPNS grant vs. inkind costs)

Costing Costs associated with local and cross-site evaluation will be represented separately and are not included in the cost of demonstration site intervention implementation. Timeline Participant Survey Development Program ACASI Pilot (est. July 14) Finalize survey (est. August 18)

IRB Approval UCSF (est. June 30) Sites Intervention implementation Thank You Questions?

Recently Viewed Presentations

  • Inside the Cost Report - SAE India

    Inside the Cost Report - SAE India

    Inside the Cost Report Tips and Suggestions on Improving Your Team's Cost Report for Next Year The Concept of the Competition For the purpose of this competition, the students are to assume that a manufacturing firm has engaged them to...
  • Virtual Camera Model

    Virtual Camera Model

    Overview Recursive Ray Tracing Shadow Feelers Snell's Law for Refraction When to stop! Recap: Light Transport Recap: Local Illumination Ambient, diffuse & specular components The sum is over the specular and diffuse components for each light Recap: Result of Ray...
  • Treatment of COPD Does Current Practice Match the Evidence

    Treatment of COPD Does Current Practice Match the Evidence

    * Systematic review with meta-analysis demonstrated the effectiveness of disease management programs for COPD. Disease management programs were defined as having two or more different components ...
  • Project Management Community Meeting

    Project Management Community Meeting

    EPLC Update. HHS EPLC Workgroup has finalized revisions to the following EPLC Artifacts: Business Needs Statement, Business Case with Alternatives Analysis, Project Process Agreement, Issue Management, and Stage Gate Review template and guide.
  • CS 1302 Computer Networks  Unit - 5  Application

    CS 1302 Computer Networks Unit - 5 Application

    We use the HEAD method to retrieve information about an HTML document (see the next section). The request line shows the method (HEAD), URL, and HTTP version (1.1). The header is one line showing that the client can accept the...
  • Recycling Presentation - kyrene.org

    Recycling Presentation - kyrene.org

    When you are finished, make a powerpoint presentation to be used to present to the classes to help them understand our recycling program at Altadena. You will also be making a poster to hang in the hallway. Include props to...
  • Speech Acts - Michael Johnson

    Speech Acts - Michael Johnson

    Examples. Boring, harassing, irritating, pleasing, or persuading someone by saying what you said are examples of perlocutionary acts. My giving a lecture on Austin doesn't conventionally . constitute. boring you, even if it as a matter of causal law does...
  • A Seminar on Invitro Invivo Correlation - Pharmawiki.in

    A Seminar on Invitro Invivo Correlation - Pharmawiki.in

    Tipnis, H, P, Bajaj A , "In vitro In vivo Correlations", Principles and Applications of Biopharmaceutics and Pharmacokinetics, 332-350 (2005). Venkateshwarlu, V, "Bioavailability and Bioequivalence", Biopharmaceutics and Pharmacokinetics, 331-356 (2004). ... A Seminar on Invitro Invivo ...